PIM1 and neoplasm: After 17 days of dosing, treatment with the pan-PIM inhibitor AZD1208 alone or savolitinib alone resulted in statistically-insignificant, tumor growth inhibition (TGI) of ~12% ± 9.6% s.e.m. relative to the vehicle-treated group (Figure 8B).